NCT06663839
A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer
StatusUnknown
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Dose Limiting Toxicity (DLT)
Timeframe: Up to 12 months
Non-Tolerated Dose (NTD)
Timeframe: Up to 12 months
Maximum Tolerated Dose (MTD)
Timeframe: Up to 12 months
Adverse Events (AEs)
Timeframe: Up to 12 months
Secondary (4)
Progression Free Survival (PFS)
Overall Survival (OS)
Pharmacokinetics - Cmax
Presence of anti-drug antibodies (ADA)
Arms and interventions
NILK-2301 Single AgentExperimental
NILK-2301 will be evaluated in patients with locally advanced or metastatic low tumor volume colorectal cancer
Drugs: Biological NILK-2301
Sites
2 sites in 1 country